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Abstract
Background: Tuberculous meningitis (TBM) is the commonest form of neurotuberculosis caused
by Mycobacterium tuberculosis bacilli (MTB). The diagnosis of TBM is often difficult. A reliable, cost-
effective and rapid diagnostic test, which can be performed in any standard pathology laboratory,
could be of help in the diagnosis of TBM. In the present study we measured the adenosine
deaminase (ADA) activity in cerebrospinal fluid (CSF) of TBM and non-TBM patients.
Method: ADA activity in CSF was determined according to a method based on the Berthlot
reaction, which is the formation of a colored indophenol complex from ammonia liberated from
adenosine, and quantified spectrophotometrically.
Results: The CSF ADA activity from TBM patients was compared with CSF ADA from non-TBM
infectious meningitis patients, and from patients with non-infectious neurological disorders. The
mean CSF ADA activity was found to be significantly higher in CSF of TBM patients, 14.31 ± 3.87
(2.99–26.94), mean ± SD with range, than in the CSF from non-TBM infectious meningitis, 9.25 ±
2.14 (4.99–13.96) and from the non-infectious neurological disorders group, 2.71 ± 1.96 (0.00–
7.68), P < 0.0001 for both comparisons. A cut-off value of 11.39 U/L/min for the TBM patients was
calculated from the mean + SD of the non-TBM patients. The ADA test gave a sensitivity of 82%
and a specificity of 83% for infectious TBM when this cut-off value was used.
Conclusion: This study demonstrated that ADA activity in the CSF of TBM patients, using a cut-
off value 11.39 U/L/min, can be useful for the early differential diagnosis of TBM. This test can be
performed in any pathology laboratory where more sophisticated methods are not available.
Background
Tuberculous meningitis (TBM) is the infection of the
meninges caused by Mycobacterium tuberculosis (MTB). The
diagnosis of TBM is complicated as it causes various clini-
cal manifestations, which overlap with those of other
chronic diseases of the central nervous system (CNS) such
as viral and pyogenic meningitis [1]. The initiation of anti-
TB medication in suspected TBM patients can often be
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delayed because of a lack of confidence in the presently
available laboratory tests [2,3]. Most of the tests devel-
oped for the early diagnosis of TBM are not sensitive [4]
and although some other tests are useful, they may not be
affordable for routine use [5,6]. A reliable and rapid diag-
nostic test, which can be performed in any standard
pathology laboratory, could be of help in diagnosis of
TBM.
Adenosine deaminase (ADA) is an enzyme that catalyzes
the deamination of adenosine, forming inosine in the
process [7]. The chief physiological function of ADA is
related to lymphocytic proliferation and differentiation
[8]. As a marker of cellular immunity, activity is found to
be elevated in those diseases in which there is a cell-medi-
ated immune response [9]. Numerous previous studies
have demonstrated that CSF-ADA estimation is useful in
the diagnosis of TBM and can differentiate TBM from nor-
mal subjects or from patients with other neurological dis-
orders [10-12]. However, the results were variable and
one study has shown that ADA is of limited value as it was
also raised in other types of meningitis especially pyo-
genic meningitis [13]. In this paper we describe a prospec-
tive study to evaluate the reliability of ADA activity in the
CSF for diagnosis in patients with TBM, patients with non-
TBM infectious meningitis and patients with non-infec-
tious neurological disease. A cut-off value for CSF ADA
activity has been calculated for the diagnosis of TBM.
Materials and methods
Patients
A total of 281 patients (TBM = 117, pyogenic meningitis =
41, viral meningitis = 19, and 104 control subjects with
non-infectious neurological disorders) were included in
the present study. Patients included in the study were
those admitted to the Neurology Department of Central
India Institute of Medical sciences (CIIMS) between 1st
January 2003 and the end of February 2004. All patients
were above the age of 20 years. CSF samples for ADA esti-
mations and other tests were obtained before starting any
treatment in all cases of neurological disorders including
viral, bacterial, and mycobacterial meningitis. The Institu-
tional Ethics Committee of Central India Institute of Med-
ical Sciences, Nagpur, approved the study.
Patient Groups (Table 1)
1. Tuberculosis Meningitis patients (n = 117)
A: Clinically confirmed cases (n = 27): Confirmed by the
presence of Mycobacterium tuberculosis in CSF by stain-
ing and/or culture.
B: Clinically suspected patients (n = 90): This group had
negative cultures with all of the following observations:
a: Sub-acute or chronic fever with features of meningeal
irritation such as headache, neck stiffness and vomiting,
with or without other features of CNS involvement.
b: CSF samples showing raised protein levels, and/or
decreased glucose (CSF: blood glucose ratio <0.5), and/or
pleocytosis with lymphocytic predominance.
c: Good clinical response to antituberculous drugs.
2. Non-TBM infectious pyogenic and viral meningitis patients (n = 
60)
A: Pyogenic meningitis (n = 41): Confirmed cases (n = 9):
Presence of pathogenic bacteria in CSF by staining and/or
culture.
Clinically suspected (n = 32): This group included the cul-
ture negative cases with all of the following observations:
a: Fever and/or signs of meningeal irritation (patients who
have undergone cranial surgery to treat tumor(s), stroke,
or head injury and who have received antibiotics), or high
Table 1: The mean ADA activity (with range) in the CSF of TBM patients (n = 117), non-TBM infectious meningitis patients (n = 60) 
and control patients with non-infectious neurological disorders (n = 104). The data are expressed as mean ± SD
Patient groups ADA activity (U/L/min) Mean ± SD Range
1. Tuberculous Meningitis (n = 117) 14.31 ± 3.87 2.99–26.94
Culture positive (n = 27) 17.67 ± 4.18 9.01–26.94
Clinically suspected (n = 90) 13.29 ± 3.16 2.99–21.02
2. Non TBM infectious meningitis (n = 60) 9.25 ± 2.14 4.99–13.96
Pyogenic meningitis (n = 41) 10.11 ± 1.99 5.11–13.96
Viral meningitis (n = 19) 7.39 ± 0.93 4.99–9.00
3. Non-infectious neurological disorders (n = 104) 2.71 ± 1.96 0.00–7.68
Headache (n = 32) 0.98 ± 0.19 0.11–1.20
Stroke (n = 29) 4.18 ± 1.19 1.92–5.83
Venous sinus thrombosis (n = 13) 1.82–4.12
Guillian-Barré syndrome (n = 12) 5.38 ± 2.16 2.63–7.68
Epilepsy (n = 6) 2.36 ± 0.79 1.01–3.18
Other neurological disorders (n = 12) 1.18 ± 0.47 0.5–1.87Cerebrospinal Fluid Research 2006, 3:5 http://www.cerebrospinalfluidresearch.com/content/3/1/5
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fever and/or signs of meningeal irritation with or without
CNS manifestations (patients who received broad-spec-
trum antibiotics).
b: CSF findings showing increased proteins, decreased
glucose (CSF: blood glucose ratio <0.2), and/or pleocyto-
sis with a predominance of polymorphonuclear cells.
c: Good clinical response to broad-spectrum antibiotics.
B: Viral meningitis patients (n = 19): This group includes
suspected patients with the following observations:
a: Acute onset of fever and symptoms and signs of menin-
geal irritation.
b: CSF samples showing mild increase in protein, glucose
often normal and pleocytosis, predominantly lym-
phocytic.
c: No clinical evidence for extra cranial tuberculosis.
3. Non-infectious neurological disorders group (n = 104)
All other patients who had no evidence of CNS or extra
CNS bacterial or viral infections were grouped in the non-
infectious/control group. Patients included in this group
had chronic intractable headache, status epilepticus,
stroke and others disorders (Table 1).
Sample collection
CSF samples were collected by standard lumbar puncture.
Approximately 3 ml of CSF was obtained; 2 ml of CSF was
used for total and differential cell count, biochemistry,
and smear for Gram's, India ink, and acid fast bacilli
(AFB) staining and the remaining CSF was used for ADA
estimation. All the samples were stored at 4°C until fur-
ther analysis.
ADA activity measurement
ADA activity in CSF was determined at 37°C according to
the method of Guisti and Galanti [14] based on the Berth-
lot reaction, that is the formation of colored indophenol
complex from ammonia liberated from adenosine and
quantified spectrphotometrically (U.V.Visible spectro-
photometer.Remi.Model C-24). One unit of ADA is
defined as the amount of enzyme required to release 1
mmol of ammonia/min from adenosine at standard assay
conditions. Results were expressed as units per litre per
minute (U/L/min). The assays were performed in tripli-
cate and blind to the diagnosis.
Data analysis
Results are expressed as mean ± SD with Range. To com-
pare the mean ADA activity between the TBM, non-TBM
infectious meningitis and non-infectious neurological
disorders groups, the Kruskal Wallis test (non-parametric
ANOVA) with the Dunnett post-test was used. A P value
less than 0.05 was considered significant. A cut off value
of ADA activity for TBM patients was calculated from the
mean plus SD of ADA activity in the non-TBM infectious
meningitis group. The sensitivity (true positive rate) for
the test was calculated as: [the number of samples in the
TBM group with ADA activity ≥ (mean+SD) of ADA activ-
ity in the non-TBM infectious meningitis group divided by
the total number of samples in TBM group] × 100. The
specificity (true negative rate) for the test was calculated
as: [the number of samples in non-TBM infectious menin-
gitis group with ADA activity < (mean+SD) of ADA activ-
ity in the non-TBM infectious meningitis group divided by
the total number of samples in non-TBM infectious men-
ingitis group] × 100.
Results
The total number of patients studied was 281. Of these, 27
were confirmed for TBM, 90 were suspected for TBM, 60
had non-TBM infectious meningitis (pyogenic meningitis,
41, and viral meningitis, 19) and 104 had other CNS dis-
orders.
Box plots of CSF ADA activity in TBM (CP-culture positive;  CS-clinically suspected), non-TBM infectious meningitis (PM-  pyogenic meningitis; VM-viral meningitis) and control group  of non-infectious neurological disorders (OTH) Figure 1
Box plots of CSF ADA activity in TBM (CP-culture positive; 
CS-clinically suspected), non-TBM infectious meningitis (PM- 
pyogenic meningitis; VM-viral meningitis) and control group 
of non-infectious neurological disorders (OTH). The plots 
show the 90th percentile (bars), 75th and 25th percentile (box) 
and median (bar in box). N = numbers of individuals in each 
group. Dashed line represents the calculated ADA cut off 
value.Cerebrospinal Fluid Research 2006, 3:5 http://www.cerebrospinalfluidresearch.com/content/3/1/5
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Table 1 depicts the mean ADA activity in the CSF of differ-
ent patient groups. The mean ADA activity in TBM
patients was 14.31 ± 3.87 (2.99–26.94), significantly
higher than the non-TBM infectious meningitis group,
9.25 ± 2.14 (4.99–13.96); P < 0.0001, and also higher
than the non-infectious neurological disorders group,
2.71 ± 1.96 (0.00–7.68); P < 0.0001. A significant differ-
ence in the mean ADA activity was noted also in the CSF
of culture-positive TBM patients, 17.67 ± 4.18 (9.01–
26.94), when compared with the clinically suspected TBM
patients, 13.29 ± 3.16 (2.99–21.02); P < 0.0001. The cut
off value of the ADA activity for the diagnosis of TBM
patients was, calculated as 9.25 + 2.14 = 11.39 U/L/min.
Box plots of the ADA activity in the CSF of culture positive
and clinically suspected TBM patients, non-TBM infec-
tious meningitis and non-infectious neurological disor-
ders groups are shown in Figure 1, together with the 90th
percentile range, 75th and 25th percentiles.
Table 2 shows the number and percentage of patients in
each group that fall above or below the cut-off value. Sen-
sitivity in the TBM group was 96% (96% of the culture
positive samples were above the cut-off value) whereas it
was only 78% in the clinically suspected group. In the
non-TBM infectious meningitis group, 24% in the pyo-
genic meningitis group were above the cut-off value, but
none of the viral meningitis samples were over the cut-off
value. For the non-infectious neurological disorder group,
none of the patients had ADA activity above the cut-off
value. The sensitivity of the ADA test to differentiate
between TBM and non-infectious meningitis was 82%
and the specificity was 83% when the cut-off value of
11.39 U/L/min was used. The 95% confidence interval for
sensitivity was 90.19 (upper limit) and 73.91 (lower
limit) while the 95% confidence interval for specifity was
88.99 (upper limit) and 77.67 (lower limit).
Discussion
TBM remains a major global health problem and even in
developed countries there is a resurgence of tuberculous
infection due to the growing number of people infected
with human immunodeficiency virus (HIV) [15,16]. Early
confirmatory diagnosis of TBM is difficult to establish
because of its pleomorphic clinical presentation [3,17].
Delayed diagnosis and treatment may be associated with
many serious CNS complications [18]. The most com-
monly used laboratory method for the definitive diagno-
sis of TBM is to demonstrate the presence of tubercle
bacilli either by smear and/or culture. However, direct
smear methods are often negative in CSF samples and cul-
turing of MTB takes 4–6 weeks to show the growth
[19,20]. Newer methods such as those involving the
amplication of bacterial DNA by the PCR and comparable
systems, are incompletely assessed and not available for
widespread use in the developing countries. The sensitiv-
ity of the PCR technique varies from 33% to 90% and the
specificity from 88% to 100% [21]. Various immu-
noassays such as antigen and/or antibody detection in
CSF samples have been developed with variable sensitivi-
ties and specificities [2,9,10,22-24]. Hence, despite exten-
sive work on TBM, only few diagnostic tests are available.
Recently we have reported on a 30 kD protein antigen
comprising of antigen 85 complex in CSF of TBM patients
by indirect ELISA method with a sensitivity of 89% and
specificity of 97% [25].
ADA has been considered as a marker of cell-mediated
immunity and its activity has been observed in various
infections including TBM [9]. Considering that both
Table 2: The number and percentage of patients positive and negative for the CSF ADA test using the diagnostic cut-off value of > 
11.39 U/L/min for the TBM patients, the non-TBM infectious meningitis patients and the control group with non-infectious 
neurological disorders. The sensitivity of the test for positive diagnosis was 82% and the specificity was 83%. The 95% confidence 
interval for sensitivity is between 73.91 and 90.19, while 95% confidence interval for specificity is between 77.67 and 88.99.
Patient groups Number of patients with ADA activity 
>11.39 U/L/min
Number of patients with ADA activity 
< 11.39 U/L/min
1. Tuberculous Meningitis (n = 117) 96 (82%) 21 (18%)
Culture positive (n = 27) 26 (96%) 1 (4%)
Clinically suspected (n = 90) 70 (78%) 20 (22%)
2. Non-TBM infectious meningitis (n = 60) 10 (17%) 50 (83%)
Pyogenic meningitis (n = 41) 10 (24%) 31 (76%)
Viral meningitis (n = 19) 0 (0%) 19 (100%)
3. Non-infectious neurological disorders (n = 104) 0 104 (100%)
Headache (n = 32) 0 32 (100%)
Stroke (n = 29) 0 29 (100%)
Venous sinus thrombosis (n = 13) 0 13 (100%)
Guillian-Barré syndrome (n = 12) 0 12 (100%)
Epilepsy (06) 0 06 (100%)
Other neurological disorders (n = 12) 0 12 (100%)Cerebrospinal Fluid Research 2006, 3:5 http://www.cerebrospinalfluidresearch.com/content/3/1/5
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humoral and cell-mediated immunity play an important
role in TBM infection, it has been suggested that ADA
activity in CSF may help differentiate TBM from non-TBM
infectious meningitis and non-infectious neurological
disorders, and this has been discussed earlier by various
workers [11,12,26].
In the present study we have calculated an ADA cut-off
value of 11.39 U/L/min in CSF for the diagnosis of TBM
infection. Using this we have demonstrated a sensitivity of
96% and 78% in the CSF of culture-positive and clini-
cally-diagnosed TBM patients, respectively. False positive
results were noted in 24% of pyogenic meningitis cases.
No other control group gave false positive results.
Earlier, various workers have reported the reliability of
CSF ADA activity in TBM patients using different cut off
values. Pettersson et al. reported sensitivity of 100% and
specificity of 99% when a cut off value of 20 U/L/min was
used, but in that study there were only three enrolled
tuberculous meningitis patients [12]. Baro et al proposed
a cut off value of 6.5 U/L/min and showed sensitivity of
83.3% and specificity of 85.3% [11]. However, this study
used only 12 cases of TBM patients, and pyogenic and
viral meningitis were not distinguished from the group
with other central nervous system diseases. Similarly
increased CSF ADA levels have been reported in child-
hood TBM with adverse neurological outcome [27]. How-
ever, Gambhir et al reported a low sensitivity of 44% and
specificity of 75% for ADA test with a cut off value 8 IU/L/
min, which showed overlap between TBM and non-TBM
patients, especially for infectious neurological disorders
like pyogenic meningitis [28].
The laboratory method for measuring ADA is inexpensive,
relatively simple to perform and can also be adapted to an
autoanalyser. It may thus be useful in laboratories with
limited resources, especially in underdeveloped and
developing countries like India where the incidence of
tuberculosis is very high and where, despite extensive
work on pulmonary and extra pulmonary tuberculosis,
only a few diagnostic kits are available for tuberculous
meningitis.
Conclusion
In conclusion, the determination of ADA activity in CSF of
TBM patients using cut off value of 11.39 U/L/min can be
useful for the early differential diagnosis of TBM and it is
cost effective. However CSF ADA should be interpreted
judiciously in the light of the patient's clinical condition
and CSF characteristics since there is a wide range of CSF
ADA activity in TBM. In addition, there is overlap with
ADA activity in some pyogenic meningitis patients. Over-
all our study suggests that measurement of ADA activity in
CSF of TBM patients with a cut off value of 11.39 U/L/min
can be useful as a supporting test for the differential diag-
nosis.
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